Investigational New Drugs

, Volume 29, Issue 4, pp 680–687

Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study

  • Cheryl Ho
  • Randeep Sangha
  • Laurel Beckett
  • Michael Tanaka
  • Derick H. Lau
  • Daniel B. Eisen
  • Rachel A. Burich
  • Paul Luciw
  • Imran Khan
  • Philip C. Mack
  • David R. Gandara
  • Angela M. Davies
PHASE I STUDIES

DOI: 10.1007/s10637-010-9396-4

Cite this article as:
Ho, C., Sangha, R., Beckett, L. et al. Invest New Drugs (2011) 29: 680. doi:10.1007/s10637-010-9396-4

Summary

Background Cetuximab is a chimeric monoclonal antibody targeting the epidermal growth factor receptor (EGFR). The recommended dosage is an initial load of 400 mg/m2 intravenously (IV) followed by a weekly maintenance dose of 250 mg/m2. It has been reported retrospectively that cetuximab efficacy was correlated with dose-related severity of skin rash. This study was prospectively designed to examine the safety and feasibility of escalating weekly doses of cetuximab, testing the hypothesis of the relationship of dose-dependent skin toxicity and efficacy. Methods Four dose levels were tested: Cetuximab 400 mg/m2 IV loading dose and 250, 300, 350, 400 mg/m2 weekly IV maintenance. There was no intra-patient dose escalation. Standard dose limiting toxicity criteria were used. Rash was evaluated using two additional validated dermatology methods: global acne grading scale (GAGS) and acne lesion counting (ALC). Tumor specimens and blood samples were obtained for correlative analyses. Results Twenty seven patients with solid tumors were enrolled: five head and neck, three pancreas, four gall bladder, two each of prostate, breast, colorectal, lung, and esophagus, and five others. Planned dose escalation was completed without reaching dose-limiting toxicity (DLT) or the maximum tolerated dose (MTD). The highest dose level was expanded to a total of 17 patients. Gr 3/4 toxicities included: lymphopenia (2), fatigue (2), and hypomagnesemia (2). One patient experienced a grade 3 rash (350 mg/m2). Sixty five percent of pts had a ≥ Gr 2 rash that was not dose dependent. In 22 evaluable patients, there was one partial response (PR) in a patient with cholangiocarcinoma (400 mg/m2) and seven patients had stable disease (SD). ALC and GAGS demonstrated no correlation with dose or response. Correlative studies evaluating k-ras, EGFR FISH status and immunologic correlatives were conducted on available tumor samples. Conclusions Cetuximab administered at 400 mg/m2 IV as a loading dose with weekly maintenance dose of 400 mg/m2 is feasible and well tolerated. There was no direct correlation of the grade of rash with dose in this group of patients with heterogenous solid tumors.

Keywords

Cetuximab Acneiform rash Solid tumors Global acne grading scale Acne lesion counting 

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Cheryl Ho
    • 1
  • Randeep Sangha
    • 2
  • Laurel Beckett
    • 3
  • Michael Tanaka
    • 3
  • Derick H. Lau
    • 3
  • Daniel B. Eisen
    • 3
  • Rachel A. Burich
    • 3
  • Paul Luciw
    • 3
  • Imran Khan
    • 3
  • Philip C. Mack
    • 3
  • David R. Gandara
    • 3
  • Angela M. Davies
    • 4
  1. 1.British Columbia Cancer AgencyVancouverCanada
  2. 2.Cross Cancer InstituteEdmontonCanada
  3. 3.University of CaliforniaSacramentoUSA
  4. 4.OSI Pharmaceuticals, Inc.BoulderUSA